

Konstantynów Łódzki, 20 February 2024

Press release

Marty Henehan will strengthen Mabion's sales operations as Vice President of Business Development for North America

- > **20 February 2024 experienced executive Marty Henehan has taken up the position of Vice President of Business Development for North America at Mabion S.A.**
- > **In his new role, Marty Henehan will be responsible for sales strategy, business partnerships and supporting the development of Business Development activities in the North American market**
- > **Marty Henehan has more than 20 years of industry experience and a track record of successful CDMO market entry strategies, having held leading positions at Pharmaron, Hospira, Therapure and August Bioservices, among others**
- > **The new Vice President of Business Development's activities will focus on the North American market, including representing Mabion at key events for the biopharmaceutical industry, including DCAT Week (March 2024) and the American Biomanufacturing Summit (April 2024)**
- > **Mabion's Business Development team now includes nine experts, who are leading extensive activities directed at customer diversification and winning new contracts for CDMO services**

*„We are building one of the most innovative companies in the CDMO industry, so we are delighted to have someone with such extensive and relevant experience from our company's perspective join the team. Marty Henehan will be responsible for sales development, strategic partnerships and most importantly supporting Business Development activities in our key market of North America” – **comments Krzysztof Kaczmarczyk, Chief Executive Officer of Mabion S.A.***

Marty Henehan has over 20 years of industry experience and a proven track record of developing successful CDMO market entry strategies and building global brands. Before joining Mabion, he was Vice President of Biologics at Pharmaron, expanding the company's C> and biologics manufacturing portfolio into North America. Previously, he held CDMO leadership positions at Hospira (now Pfizer One2One), Therapure (now part of Resilience) and August Bioservices. Earlier in his career, Marty held leadership roles at large life science companies including Boehringer Ingelheim, Oscient Pharmaceuticals and Specialty Labs. Marty holds an MBA in Finance and Management from the University of Notre Dame, a certificate in pharmaceutical and biologics leadership from the Wharton School at the University of Pennsylvania and a bachelor's degree in Marketing from DePaul University.

*„Mabion has built a clear path for transformation into a fully integrated biologics CDMO, has an upgraded and modern manufacturing facility and provides best-in-class quality and customer service, which attracted me to take on the role of Vice President of Business Development. Strengthening the business to develop the sales offering in North America is a natural next step for Mabion, and the organization's more than 17 years of experience and collaboration with Novavax to produce the antigen for the vaccine for COVID-19, provides a solid foundation to build an attractive offering for potential customers in the US. I will already be representing Mabion at one of the most important conferences for the biopharmaceutical industry in the world, DCAT Week in New York next month” – **says Marty Henehan, Vice President of Business Development for North America at Mabion S.A.***

Mabion continues to intensify its efforts directed at diversifying its customers and winning new contracts in the contract manufacturing of biological drugs. The Business Development team now consists of nine people and will support Marty Henehan's activities in the North American market, focused on acquiring new customers for the Company's CDMO services.

*„For the position of Vice President of Business Development, we were not only looking for a person with a strong understanding of the CDMO market and the broad product offering we have built at Mabion but more importantly a person with proven credentials in successfully implementing sales strategies and establishing business partnerships. Marty quickly identified the opportunities facing the Company today, with a clear development path in the form of the 2023-2027 Strategy and a modernized manufacturing facility that addresses the current needs and challenges of commercial companies interested in working with a CDMO-like entity. I believe that our cooperation will contribute to the achievement of our goals and together we will build a recognizable brand in the North American market” – **adds Adam Pietruszkiewicz, Chief Commercial Officer at Mabion S.A.***

In April 2023, Mabion adopted a long-term Strategy for 2023-2027, which aims to transform the Company into a fully integrated biologics CDMO and build its position as a recognizable player in the global contract drug development and contract manufacturing market. The strategy involves significantly expanding manufacturing assets, expanding the range of technologies used, strengthening the business development department, adapting internal processes to work with multiple customers and offering a wide range of services as a fully integrated CDMO.

The first phase of the investment, planned for 2023-2024, primarily involves the modernization of Mabion's existing manufacturing facility in Konstancin-Łódzki. As a result of the construction, assembly and installation work carried out in the second half of 2023, Mabion now has a modern and technologically diversified plant with the characteristics of the facility changed from a single-product manufacturing plant to the ability to run different processes at the same time. The upgraded plant is equipped with a set of bioreactors with a total capacity of more than 10,000 L, of which the two largest bioreactors are Kuhners at 2,500 L each using orbital shaking technology, and two more are Cytiva bioreactors at 2,000 L each using classical mixing technology. As a result, Mabion is a comprehensive biologics CDMO, capable of supporting pharmaceutical companies from early-stage drug development to large-scale commercial production.

Contact for media and individual investors

Michał Wierzchowski
+48 531 613 067
+48 22 440 14 40
michal.wierzchowski@ccgroup.pl

Mardoniusz Maćkowiak
+48 605 959 539
+48 22 440 14 40
mardoniusz.mackowiak@ccgroup.pl

Contact for institutional investors and analysts

Piotr Owdziej
+48 697 612 913
+48 22 440 14 40
piotr.owdziej@ccgroup.pl

Katarzyna Mucha
+48 697 613 712
+48 22 440 14 40
katarzyna.mucha@ccgroup.pl

Information about Mabion S.A.

Mabion S.A. (WSE: MAB) is a Polish biopharmaceutical company founded in 2007, which is undergoing a transformation into a fully integrated contract development and manufacturing organization (CDMO) providing a broad spectrum of services in the segment of small and medium-sized projects at various stages of development (from early-stage discovery to commercial manufacturing). Mabion's competencies include the selection of protein expression technologies, their purification, GMP-standard manufacturing activities (obtaining Active Substances "Drug Substance" and Finished Products "Drug Product"), the development of analytical tools (for structural, functional, and physicochemical characterization), clinical development, clinical analytics, and a full range of regulatory activities in the development and operational areas. The company signed a record contract with Novavax in October 2021 for the commercial production of antigen for the COVID-19 vaccine, which it has since steadily expanded through further services under SOWs (Statements of Work) concluded and annexes signed, adding, among other things, another vaccine product based on the Omicron variant. In line with the Strategy announced in April 2023, the Company's objective is to establish itself as a recognizable player in the global contract manufacturing and contract drug development market and to complete the full transformation of Mabion into an integrated biologics CDMO company. Mabion is a public Company, listed on the Warsaw Stock Exchange.

For more information about the Company, please visit www.mabion.eu